Gain Therapeutics
(NASDAQ:GANX)
$3.16
-0.20[-5.95%]
At close: Apr 12
$3.16
0[0.00%]
After Hours: 5:21PM EDT
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$5.00
Consensus Price Target1
$8.33

Gain Therapeutics Stock (NASDAQ:GANX), Analyst Ratings, Price Targets, Predictions

Gain Therapeutics Inc has a consensus price target of $8.33, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co. on April 1, 2024, March 27, 2024, and December 4, 2023. With an average price target of $8 between HC Wainwright & Co., Chardan Capital, and HC Wainwright & Co., there's an implied 153.16% upside for Gain Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Dec 23
1
Mar
1
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Chardan Capital
Maxim Group
Oppenheimer
BTIG

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Gain Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
04/01/2024GANXBuy Now
Gain Therapeutics
$3.16184.81%HC Wainwright & Co.
Raghuram Selvaraju
→ $9ReiteratesBuy → BuyGet Alert
03/27/2024GANXBuy Now
Gain Therapeutics
$3.1689.87%Chardan Capital
Keay Nakae
→ $6ReiteratesBuy → BuyGet Alert
12/04/2023GANXBuy Now
Gain Therapeutics
$3.16184.81%HC Wainwright & Co.
Raghuram Selvaraju
$10 → $9MaintainsBuyGet Alert
09/18/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
09/12/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%Maxim Group
Jason McCarthy
→ $10Initiates → BuyGet Alert
08/31/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
08/14/2023GANXBuy Now
Gain Therapeutics
$3.1689.87%Chardan Capital
Keay Nakae
→ $6ReiteratesBuy → BuyGet Alert
08/14/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
06/12/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%Oppenheimer
Hartaj Singh
→ $10ReiteratesOutperform → OutperformGet Alert
05/15/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $10ReiteratesBuy → BuyGet Alert
05/15/2023GANXBuy Now
Gain Therapeutics
$3.1689.87%Chardan Capital
Keay Nakae
$5.75 → $6MaintainsBuyGet Alert
05/01/2023GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
→ $10Reiterates → BuyGet Alert
03/27/2023GANXBuy Now
Gain Therapeutics
$3.1681.96%Chardan Capital
Keay Nakae
$4 → $5.75MaintainsBuyGet Alert
12/09/2022GANXBuy Now
Gain Therapeutics
$3.1626.58%Chardan Capital
Keay Nakae
→ $4Initiates → BuyGet Alert
11/25/2022GANXBuy Now
Gain Therapeutics
$3.16216.46%Oppenheimer
Hartaj Singh
$30 → $10MaintainsOutperformGet Alert
11/14/2022GANXBuy Now
Gain Therapeutics
$3.16216.46%HC Wainwright & Co.
Raghuram Selvaraju
$12 → $10MaintainsBuyGet Alert
11/14/2022GANXBuy Now
Gain Therapeutics
$3.16216.46%BTIG
Thomas Shrader
$30 → $10MaintainsBuyGet Alert
08/19/2022GANXBuy Now
Gain Therapeutics
$3.1658.23%B. Riley Securities
Mayank Mamtani
$11 → $5DowngradeBuy → NeutralGet Alert
03/29/2022GANXBuy Now
Gain Therapeutics
$3.16406.33%B. Riley Securities
Mayank Mamtani
$21 → $16MaintainsBuyGet Alert

FAQ

Q

What is the target price for Gain Therapeutics (GANX)?

A

The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $9.00 expecting GANX to rise to within 12 months (a possible 184.81% upside). 12 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Gain Therapeutics (GANX)?

A

The latest analyst rating for Gain Therapeutics (NASDAQ: GANX) was provided by HC Wainwright & Co., and Gain Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Gain Therapeutics (GANX)?

A

There is no last upgrade for Gain Therapeutics.

Q

When was the last downgrade for Gain Therapeutics (GANX)?

A

The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.

Q

Is the Analyst Rating Gain Therapeutics (GANX) correct?

A

While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a reiterated with a price target of $0.00 to $9.00. The current price Gain Therapeutics (GANX) is trading at is $3.16, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch